Thus, our results suggest that Jak2/STAT6/c-Myc pathway contributes to the progression of Ph+ ALL, and inhibition of this pathway may provide a new potential therapy for Ph+ ALL patients. The gene discussed is JAK2; the disease is acute lymphoblastic leukemia.